학술논문
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Document Type
Article
Author
Source
In: Breast Cancer Research and Treatment . (Breast Cancer Research and Treatment, 1 January 2017, 161(1):63-72)
Subject
Language
English
ISSN
15737217
01676806
01676806